Acute Lymphoblastic Leukemia (ALL) is a fast-progressing cancer of the blood and bone marrow, primarily affecting children but also occurring in adults. Recent advances in cancer research have significantly improved the understanding and treatment of ALL. Innovative therapies, such as chimeric antigen receptor (CAR) T-cell therapy, have shown promise in targeting and eradicating leukemic cells with precision. Additionally, advancements in genetic profiling and molecular diagnostics have enabled personalized treatment approaches, increasing remission rates and reducing relapse. Ongoing clinical trials are exploring novel drug combinations and immunotherapies to enhance patient outcomes further. As research continues, the goal is to develop more effective, less toxic treatments, offering hope for improved survival and quality of life for ALL patients.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China